Daré Bioscience to Host Second Quarter 2022 Financial Results and Company Update Conference Call and Webcast on August 9, 2022
August 02 2022 - 8:00AM
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s
health innovation, today announced that it will host a conference
call and live webcast at 4:30 p.m. Eastern Time on
Tuesday, August 9, 2022, to review its financial results for the
quarter ended June 30, 2022 and to provide a Company update.
To access the conference call via phone, dial
(800) 715-9871 (U.S.) or (646) 307-1963 (international). The
conference ID number for the call is 3817141. The live webcast can
be accessed under “Presentations, Events & Webcasts" in the
Investors section of the Company's website at
http://ir.darebioscience.com. Please log in approximately 5-10
minutes prior to the call to register and to download and install
any necessary software. To access the replay, please call (800)
770-2030 (U.S.) or (609) 800-9909 (international). The conference
ID number for the replay is 3817141. The call and webcast replay
will be available until August 23, 2022.
About Daré Bioscience
Daré Bioscience is a biopharmaceutical company
committed to advancing innovative products for women’s health. The
company’s mission is to identify, develop and bring to market a
diverse portfolio of differentiated therapies that prioritize
women's health and well-being, expand treatment options, and
improve outcomes, primarily in the areas of contraception,
fertility, and vaginal and sexual health.
Daré’s first FDA-approved product,
XACIATO™ (clindamycin phosphate) vaginal gel, 2%, is a
lincosamide antibacterial indicated for the treatment of bacterial
vaginosis in female patients 12 years of age and older, which is
under a global license agreement with Organon. XACIATO is a clear,
colorless, viscous gel, to be administered once intravaginally as a
single dose. Daré’s portfolio also includes potential
first-in-category candidates in clinical development: Ovaprene®, a
novel, hormone-free monthly contraceptive whose U.S. commercial
rights are under a license agreement with Bayer; Sildenafil Cream,
3.6%, a novel cream formulation of sildenafil to treat female
sexual arousal disorder utilizing the active ingredient in Viagra®;
and DARE-HRT1, a combination bio-identical estradiol and
progesterone intravaginal ring for hormone therapy following
menopause. To learn more about XACIATO, Daré’s full portfolio of
women’s health product candidates, and Daré’s mission to deliver
differentiated therapies for women, please visit
www.darebioscience.com.
Daré may announce material information about its
finances, product and product candidates, clinical trials and other
matters using the Investors section of its website
(http://ir.darebioscience.com), SEC filings, press releases, public
conference calls and webcasts. Daré will use these channels to
distribute material information about the company, and may also use
social media to communicate important information about the
company, its finances, product and product candidates, clinical
trials and other matters. The information Daré posts on its
investor relations website or through social media channels may be
deemed to be material information. Daré encourages investors, the
media, and others interested in the company to review the
information Daré posts in the Investors section of its website and
to follow these Twitter accounts: @SabrinaDareCEO and
@DareBioscience. Any updates to the list of social media channels
the company may use to communicate information will be posted in
the Investors section of Daré’s website.
Contacts:
Investor Relations Lee Roth, Sr. Vice
PresidentBurns McClellanLroth@burnsmc.com 212.213.0006
OR
Media on behalf of Daré Bioscience, Inc.:Jake RobisonEvoke
Canale jake.robison@evokegroup.com 619.849.5383
Source: Daré Bioscience, Inc.
Dare Bioscience (NASDAQ:DARE)
Historical Stock Chart
From Jun 2024 to Jul 2024
Dare Bioscience (NASDAQ:DARE)
Historical Stock Chart
From Jul 2023 to Jul 2024